Immunovant Inc's stock surged by 10.48%, reaching a 20-day high amid a challenging market environment, with the Nasdaq-100 down 0.83% and the S&P 500 down 0.10%.
The increase in stock price is attributed to Immunovant's announcement of a $550 million underwritten offering to support the launch of IMVT-1402 for Graves' disease. The controlling shareholder, Roivant Sciences Ltd., has committed to purchasing shares in the offering, reflecting confidence in the company's future and enhancing market support. This strategic move is expected to provide sufficient capital for operating expenses and capital expenditures leading up to the drug's potential launch.
The successful launch of IMVT-1402 could significantly bolster Immunovant's position in the autoimmune disease market, opening new revenue streams and driving long-term growth for the company.
Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 37.00 USD with a low forecast of 22.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast IMVT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMVT is 37.00 USD with a low forecast of 22.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 26.060
Low
22.00
Averages
37.00
High
54.00
Current: 26.060
Low
22.00
Averages
37.00
High
54.00
Truist
Danielle Brill
Hold
maintain
$16 -> $22
2026-01-08
Reason
Truist
Danielle Brill
Price Target
$16 -> $22
AI Analysis
2026-01-08
maintain
Hold
Reason
Truist analyst Danielle Brill raised the firm's price target on Immunovant to $22 from $16 and keeps a Hold rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Wolfe Research
Andy Chen
Peer Perform -> Outperform
upgrade
2026-01-06
Reason
Wolfe Research
Andy Chen
Price Target
2026-01-06
upgrade
Peer Perform -> Outperform
Reason
Wolfe Research analyst Andy Chen upgraded Immunovant to Outperform from Peer Perform.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMVT
Unlock Now
Guggenheim
Yatin Suneja
Buy
downgrade
$44 -> $41
2025-12-18
Reason
Guggenheim
Yatin Suneja
Price Target
$44 -> $41
2025-12-18
downgrade
Buy
Reason
Guggenheim analyst Yatin Suneja lowered the firm's price target on Immunovant to $41 from $44 and keeps a Buy rating on the shares following the company's recent $550M equity raise. The firm cites a higher share count and modest dilution, partially offset by an extended cash runway and strengthened balance sheet, for its adjusted target.
Truist
Hold
initiated
$16
2025-10-14
Reason
Truist
Price Target
$16
2025-10-14
initiated
Hold
Reason
Truist initiated coverage of Immunovant with a Hold rating and $16 price target. IMVT1402 appears to drive deeper IgG reductions than other FcRn inhibitors, but the firm thinks 1402 is too far behind in certain indications to gain meaningful traction in the market, the analyst tells investors. While aligned with the strategy of pursuing indications where 1402 would be first in class, the firm also notes that "meaningful de-risking" for these is not expected until 2027.
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
